

# Identify biomarkers included in competitor trials


This guide will help you benchmark competitor clinical trials and identify biomarkers to potentially include in your next studies.

Cortellis editors gather insights from clinical trial registries, conferences, press releases and other sources to help you access that information all in one place. They also index clinical trials by condition, target, sponsor, biomarkers and many other fields -available in filters- allowing you to quickly understand competitor trials details.

Cortellis Clinical Trials Intelligence provides you with biomarkers names, roles and categories in comparative tables and charts for easy visualization.

**Example:** Identify biomarkers included in competitor clinical trials studying Crohn's disease in patients in remission.

1. Quick search 'Crohn's disease' and select 'Clinical Trials' on the left menu under Report Type.



The screenshot shows the Cortellis Clinical Trials Intelligence interface. At the top, there is a search bar with the text "crohns disease" and a green box highlighting the "Index" button. Below the search bar, there are tabs for "GenAI Enhanced Search", "Advanced search", "Structure search", and "Search history". The main content area displays "2856 results found for index Search for the search term 'crohns disease'". On the left, there is a "Report Type" sidebar with "Clinical Trials (2856)" selected. The main table shows search results with columns: Title, Condition, Patient Segment, Biomarkers, and Int. The first result is "Observational Investigation of the CDED in a Real World IBD Clinic" with the condition "Crohns disease" and biomarkers "Body Mass Index ; Body height ; Calprotectin ; Muscle strength ; Total body mass ;".

Report Type	Results	Per page : 25	Sort by: Relevance	Order Columns
<a href="#">Show selected only</a> Broker Research (19482) <b>Clinical Trials (2856)</b>	<input checked="" type="checkbox"/> Title <input checked="" type="checkbox"/> <a href="#">Observational Investigation of the CDED in a Real World IBD Clinic</a>	Condition Filters : [0] <b>Crohns disease</b>	Patient Segment Filters : [0] <b>Crohns disease</b> - Subjects with Protocol Specified Age Characteristics; <b>Crohns</b>	Biomarkers Filters : [0] Body Mass Index ; Body height ; Calprotectin ; Muscle strength ; Total body mass ;

- Apply filters to narrow down results by Condition: 'Crohns disease' and Patient segment: 'Crohns disease in remission'.

SHOW ALL FILTERS

☒ Non-Hierarchical List
 ☐ Hierarchical List

Select filter view
 

Frequency

Condition
Patient Segment
Biomarkers
Biomarker Type
Biomarker Role
Drug Pipeline Interventions

☐ Crohns disease - Subjects with Active Crohns Disease (242)
 ☐ Crohns disease - Subjects with H/O Treatment with Crohns Disease Medication (168)
 ☐ Crohns disease - Subjects by disease severity - Subjects with Moderate to Severe Crohns Disease (131)
 ☐ Crohns disease - Subjects with Treatment Resistant Disease (122)
 ☒ Crohns disease - Subjects by disease severity - Subjects with Crohns Disease in Remission (65)

- A comparative results table allows you to evaluate biomarkers, primary endpoint completion dates, recruitment status and more (please scroll to the right to see more). Click on the title of a trial of interest to read more details.

Title	Condition	Patient Segment	Biomarkers	Interventions	Recruitment Status
	Filters : [0]	Filters : [1] <input type="button" value="Clear"/>	Filters : [0]		Filters : [0]
<a href="#">The Use of WeChat Mini Program during Induced Remission in the Management of Early Crohn's Disease Patients: a non-inferiority trial</a>	Crohns disease; Inflammatory bowel disease	Crohns disease - Subjects by disease severity - Subjects with Crohns disease in Remission; Crohns disease - Subjects by disease severity - Subjects with Mild to Moderate Crohns disease; Crohns disease - Subjects with Active	C-reactive protein	WeChat Mini Program alone	Not yet recruiting
<a href="#">ACHILLE: Impact of Different Types of Physical Activity in Patients With Chronic Inflammatory Bowel Disease</a>	Crohns disease; Inflammatory bowel disease; Ulcerative colitis	Crohns disease - Subjects by disease severity - Subjects with Crohns disease in Remission; Ulcerative colitis - Subjects by disease severity - Ulcerative Colitis Subjects in Remission	Heart rate ; Maximal oxygen uptake ; Muscle strength	Endurance training alone; Resistance training alone	Completed

4. The Protocols & Results tab provides details of trial arms, results and adverse events (if any).

Impact of Different Types of Physical Activity in Patients With Chronic Inflammatory Bowel Disease	
Snapshot	Highlight <input type="checkbox"/> Search Terms & Synonyms < Previous Next >
<b>Protocol &amp; Results</b>	<p>PROTOCOL &amp; RESULTS</p> <p>AIMS &amp; SCOPE</p> <p>This is a prospective interventional study. The investigators will include patients in clinical remission who are on stable treatment. These IBD patients will be followed to analyze the effects of physical activity on their inflammatory disease.</p> <p>PROTOCOL DESCRIPTION TEXT</p> <p>Different exercises will be offered to two separate groups of randomly distributed patients: the first group will perform muscle building exercises while the other group will be offered aerobic exercises. There will also be a control group that does not initially benefit from a specific physical activity program. However, this group will be integrated into one of the other two groups after the 10-week follow-up. All three groups will perform the same baseline tests. These will be of different types: physical tests, biological tests and quality of life questionnaires.</p> <p>Group 1: this group will perform aerobic type exercises. Initially, patients will perform continuous exercises of progressive intensity in order to adapt to this kind of effort. Group 2: patients in this group will perform lower limb strengthening exercises to improve the maximum strength of different muscle groups. Group 3: no intervention.</p>
<ul style="list-style-type: none"> <li>Alms &amp; Scope</li> <li>Protocol Description</li> <li>Trial Arms</li> <li>Regimens</li> <li>Results</li> <li>Adverse Events</li> <li>Treatment</li> </ul>	


5. The Subjects & Measurements tab displays eligibility criteria, biomarkers and patient segmentation as well as primary and secondary endpoints included in this trial.

Protocol & Results	SUBJECTS & MEASUREMENTS	
<b>Subjects &amp; Measurements</b>	ELIGIBILITY CRITERIA	
<ul style="list-style-type: none"> <li>Eligibility Criteria</li> <li>Outcome Measures</li> <li>Patient Segmentation</li> <li>Biomarkers</li> </ul>	Inclusion Criteria Text	<ul style="list-style-type: none"> <li>Patients in remission defined by a Harvey Bradshaw Index 5 in Crohn's disease (CD) and a clinical Mayo 3 with no sub-score&gt;1 in ulcerative colitis (RCUH) with stable treatment, without corticosteroid for 4 months. - Patients accepting the study protocol</li> </ul>
	Inclusion Criteria Index	<ul style="list-style-type: none"> <li>Crohns disease <ul style="list-style-type: none"> <li>Subjects with Crohn's Disease in Remission</li> </ul> </li> <li>Crohns disease <ul style="list-style-type: none"> <li>Protocol Specified Other Inclusion Criteria</li> </ul> </li> <li>Ulcerative colitis</li> </ul>


Scroll down to identify biomarkers included. Further information on biomarkers can be found in Cortellis Drug Discovery Intelligence, depending on your company's subscription.

BIOMARKERS			
Name		Role	Type
Heart rate	<a href="#">View in CDDI</a>	Therapeutic effect marker	Physiological
Maximal oxygen uptake		Therapeutic effect marker	Physiological
Muscle strength	<a href="#">View in CDDI</a>	Therapeutic effect marker	Physiological

6. Back in the results page, you can change views at the top right to display a bar chart and visualize the top 10 biomarkers included in these trials. Click on any of the bars to display the relevant group of trials as a table.



7. Similarly change the Y-axis and click 'Go' to visualize types and roles of biomarkers according to your interests.



To find out what's included in your subscription, contact your Clarivate account manager or **LS Product Support**.